Streetbeat News

UCBJF

UCB SA

https://www.ucb.com

CEO

Jean-Christophe Tellier

Industry

Pharmaceutical Preparation Manufacturing

Open

185.45

Mkt cap

36B

Volume

High

191.85

P/E Ratio

32.14

52-wk high

209.66

Low

181.73

Div yield

0.01

52-wk low

116.60

The article discusses the potential of United Community Banks (UCB) as a strong dividend stock, highlighting the benefits of dividends for shareholders.

Portfolio Pulse from

February 12, 2025 | 6:00 pm

United Community Banks (UCB) has been upgraded to a Zacks Rank #1 (Strong Buy) due to growing optimism about its earnings prospects, indicating potential upward movement in its stock price.

Portfolio Pulse from

February 06, 2025 | 6:15 pm

United Community Banks (UCB) is highlighted as a top dividend stock, emphasizing the benefits of dividends for shareholders. The article explores whether UCB is a strong candidate for dividend-focused portfolios.

Portfolio Pulse from

January 27, 2025 | 6:00 pm

United Community Banks, Inc. (NYSE:UCB) held its Q4 2024 earnings call on January 22, 2025. Key participants included CEO Lynn Harton, CFO Jefferson Harralson, and other executives. Analysts from Raymond James, KBW, Janney Montgomery Scott, and D.A. Davidson participated in the call.

Portfolio Pulse from

January 22, 2025 | 11:00 pm

United Community Banks (UCB) reported its Q4 earnings, providing insights into its performance compared to Wall Street estimates and year-ago values.

Portfolio Pulse from

January 22, 2025 | 3:45 pm

United Community Banks (UCB) reported Q4 earnings of $0.63 per share, surpassing the Zacks Consensus Estimate of $0.56 and last year's $0.53 per share.

Portfolio Pulse from

January 22, 2025 | 3:00 pm

United Community Banks (UCB) is preparing to release its Q4 earnings for the quarter ended December 2024. Investors are advised to look beyond Wall Street's top-and-bottom-line estimates and focus on key metrics for a deeper insight into the company's potential performance.

Portfolio Pulse from

January 16, 2025 | 3:30 pm

United Community Banks (UCB) is expected to report earnings growth in its upcoming release, with a likely earnings beat due to favorable conditions.

Portfolio Pulse from

January 15, 2025 | 4:15 pm

Biogen and UCB's Phase 3 study of dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, showing improvement over placebo. A second Phase 3 trial is planned for 2024. Biogen's stock rose 1.66% in premarket trading.

Portfolio Pulse from Vandana Singh

September 24, 2024 | 12:19 pm

Truist Securities initiated coverage on Longboard Pharmaceuticals (NASDAQ:LBPH), highlighting its high-value epilepsy assets. The company plans to advance its lead drug, bexicaserin, into Phase 3 trials. Bexicaserin has shown promising results in reducing seizures and has received FDA Breakthrough Therapy designation. Truist rates LBPH as a Buy with a $60 price target, citing bexicaserin's superior safety and potential to expand the epilepsy market.

Portfolio Pulse from Vandana Singh

September 10, 2024 | 6:13 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.